Logo
search
  • Analytics
  • Backtesting
  • Options
  • Resources
  • Go Prime Go Prime
  • Menu
  • Menu

ERIS

Current Price

1359.6038.85 (2.94%)

|

H: 1377

L: 1280.6

  • BSE: 540596
  • |
  • NSE: ERIS
  • |
  • ISIN: INE406M01024
  • |
  • INDUSTRY: Pharmaceuticals

Open Price

1309.8

Prev. Close

1320.75

Price Table

* Prices are based on daily market changes.
DateOpenHighLowCloseVolumeDelivery %20-Day sma50-Day sma200-Day sma
09 Apr, 20251309.801377.001280.601359.601,95,47822.701335.101294.251283.75
08 Apr, 20251283.351350.001256.251320.7569,56931.421330.701290.151282.10
07 Apr, 20251097.201290.001097.201274.651,30,00847.041328.451287.751280.70
04 Apr, 20251360.001370.001305.151321.301,45,08653.231328.201287.201279.60
03 Apr, 20251383.151420.001357.701368.2580,61244.201323.751285.551278.00
02 Apr, 20251390.001399.001362.751372.652,19,05184.391315.151283.501276.30
01 Apr, 20251400.001406.951370.001390.0064,06842.161305.551281.651274.50

Day High Low Range

TimeLowestHighestVolume
09.30 AM1280.601309.803205.00
09.45 AM1280.601309.805775.00
10 AM1280.601309.807687.00
11 AM1280.601309.8016157.00
12 PM1280.601313.0021070.00
1 PM1280.601324.55114388.00
2 PM1280.601324.55118175.00
3 PM1280.601377.00150148.00

Past Performance & Moving Averages

Day’sLow high rangeSMAStock performanceNifty performance
10 DAY
1097.20
-
1430.00
1354.47-3.59%-2.6%
20 DAY
1097.20
-
1499.00
1335.12-2.17%-1.91%
50 DAY
1097.20
-
1499.90
1294.279.13%-1.17%
100 DAY
1097.20
-
1593.90
1329.74-1.58%-4.51%
200 DAY
987.10
-
1593.90
1283.740.21%-12.81%
YTD
1097.20
-
1499.90
1288.83-0.32%-4.36%
52 Week
815.85
-
1593.90
1208.4620.62%-8.71%

PIVOT POINTS

NAMES4S3S2S1PIVOT POINTSR1R2R3R4
CLASSIC-1174.251215.251268.001309.001361.751402.751455.50-
WOODIE‘S--1218.191273.881311.941367.631405.69--
FIBONACCI-1215.251251.041273.191309.001344.811366.961402.75-
CAMARILLA1269.191294.971303.561312.16-1329.341337.941346.531372.31

CPR Levels

LTP: 1359.60
PDH: 1350.00
PDL: 1256.25
S4
1146.27
S3
1204.73
S2
1242.67
S1
1301.13
| CPR |
BC: 1328.80
P: 1339.07
TC: 1349.33
R1
1397.53
R2
1435.47
R3
1493.93
R4
1531.87
  • ERIS is currently trading Above CPR levels which signifies Bullishness.
  • Today's CPR is comparatively Wider and unlikely to make a trending move today.
  • Day's opening range is 1280.6 ~ 1309.8.
  • Price is currently trading Above the day's opening range staying Above 1350 signifies Bullishness.

Trend Analysis

Short term trend: Up
Medium term trend: Not Clear
Long term trend: Not Clear

Key Data

Market capBook valuestock p/eDividend yieldroceroesales growth (3Y)face value (3Y)
18510.26 CR.190.0035.900.71% 11.30% 16.40%18.00% 1.00

Profile

ERIS It was incorporated as “Eris Lifescience Private Limited” as on January 25, 2007, as a private limited company under the Companies Act 1956, at Ahmedabad, along with a certificate of incorporation granted by the Registrar of Companies, Gujarat, Dadra, and Nagar Haveli. According to a resolution of the Shareholders dated February 5, 2007, the company name was changed to “Eris Lifesciences Private Limited” and a fresh certificate of incorporation was being issued by the Registrar of Companies, Gujarat, Dadra, and Nagar Haveli as on February 9, 2007. Further, according to a conversion of the company to a public limited company, and as approved by the Shareholders via a resolution dated January 31, 2017, the company name was changed to “Eris Lifesciences Limited,” and the RoC also issued a fresh certificate of incorporation as on February 2, 2017.

Some of the Milestones:

  • 2007:
  • The incorporation of the company took place.
  • It launched the “Eris” division focused on the cardiology and diabetes segment.
  • 2008: It launched “Nikkos” division focused on gastroenterology and orthopedics segment.
  • 2009: It launched the “Adura” division focused on the cardiology and diabetes segment.
  • 2011: It launched the “Montana” division focused on the gynecology and pediatrics segment.
  • 2012: It launched the “Inspira” division focused on the cardiology segment.
  • 2014:
  • It launched the “Victus” division focused on the anti-diabetes segment.
  • It also set up the Assam Facility by the Company.
  • 2015: It launched the “Eris 2” division focused on the pain management segment.
  • 2016:
  • It acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now, Aprica Pharmaceuticals Private Limited).
  • It acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited.
  • It acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited.
  • 2017: It acquired the trademarks ‘UNION’, ‘REUNION’ and ‘BON UNION.’

Some of the Achievements:

  • 2013:
  • Frost & Sullivan awarded it the ‘Competitive Strategy Leadership’ award.
  • It was awarded the ‘Emerging Companies Excellence’ award for scalability of the business model and managing operational efficiencies by Business Today and Yes Bank.